# Theracos clinical trials: 21 on ClinicalTrials.gov (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 21 trials with Theracos as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Theracos: 21 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/theracos

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 21
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 21 newest of 21, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| June 15, 2018 | NCT03557658 | Safety and Efficacy of Bexagliflozin in Subjects With Moderate Hepatic Impairment | Theracos | Phase 1 | Completed | Type2 Diabetes Mellitus | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03557658) |
| May 2, 2018 | NCT03514641 | An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin for the Management of Essential Hypertension | Theracos | Phase 2/3 | Completed | Essential Hypertension | 673 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03514641) |
| January 31, 2018 | NCT03417076 | Absolute Bioavailability Study With Bexagliflozin | Theracos | Phase 1 | Withdrawn | Type 2 Diabetes Mellitus | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03417076) |
| September 28, 2017 | NCT03296800 | Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects | Theracos | Phase 1 | Completed | Type 2 Diabetes Mellitus | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03296800) |
| August 24, 2017 | NCT03259789 | Safety and Efficacy of Bexagliflozin Compared to Placebo as Add-on Therapy to Metformin in Type 2 Diabetes Subjects | Theracos | Phase 3 | Completed | Type2 Diabetes Mellitus | 351 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03259789) |
| June 23, 2017 | NCT03197324 | Bexagliflozin Drug/Drug Interaction Study With Digoxin | Theracos | Phase 1 | Completed | Type2 Diabetes Mellitus | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03197324) |
| May 30, 2017 | NCT03167411 | Bexagliflozin Drug/Drug Interaction Study With Exenatide Injection | Theracos | Phase 1 | Completed | Type2 Diabetes Mellitus | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03167411) |
| April 14, 2017 | NCT03115112 | Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects | Theracos | Phase 3 | Completed | Type 2 Diabetes Mellitus | 386 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03115112) |
| November 4, 2016 | NCT02956044 | Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin | Theracos | Phase 1 | Completed | Type2 Diabetes Mellitus | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02956044) |
| July 19, 2016 | NCT02836873 | Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment | Theracos | Phase 3 | Completed | Type 2 Diabetes Mellitus | 312 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02836873) |
| June 30, 2016 | NCT02820298 | Study to Evaluate the Effects of a High-Fat Meal on Bexagliflozin in Healthy Subjects | Theracos | Phase 1 | Completed | Type 2 Diabetes Mellitus | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02820298) |
| May 11, 2016 | NCT02769481 | Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects | Theracos | Phase 3 | Completed | Type 2 Diabetes Mellitus | 426 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02769481) |
| March 22, 2016 | NCT02715258 | Safety and Efficacy of Bexagliflozin as Monotherapy in Patients With Type 2 Diabetes | Theracos | Phase 3 | Completed | Type 2 Diabetes Mellitus | 210 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02715258) |
| September 23, 2015 | NCT02558296 | Bexagliflozin Efficacy and Safety Trial | Theracos | Phase 3 | Completed | Type 2 Diabetes Mellitus | 1,700 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02558296) |
| March 17, 2015 | NCT02390050 | A Dose Range Finding Study to Evaluate the Effect of Bexagliflozin Tablets in Subjects With Type 2 Diabetes Mellitus | Theracos | Phase 2 | Completed | Diabetes Mellitus, Type 2 | 292 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02390050) |
| June 21, 2011 | NCT01377844 | Efficacy and Safety of EGT0001442 in Patients With Type 2 Diabetes Mellitus | Theracos | Phase 2 | Completed | Diabetes Mellitus | 288 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01377844) |
| July 1, 2010 | NCT01155531 | Safety & Tolerability of a Combination of Antidepressant and Peptic Ulcer Drug in Overweight Healthy Subjects | Theracos | Phase 1 | Completed | Obesity | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01155531) |
| December 10, 2009 | NCT01029704 | Safety and Efficacy Study of EGT0001442 in Subjects With Type 2 Diabetes Mellitus | Theracos | Phase 2 | Completed | Diabetes Mellitus Type 2 | 151 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01029704) |
| June 18, 2009 | NCT00924053 | Safety, Tolerability and Pharmacokinetics Study of EGT0001474 in Subjects With Type 2 Diabetes | Theracos | Phase 1 | Completed | Diabetes Mellitus Type 2 | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00924053) |
| March 2, 2009 | NCT00854113 | Study to Determine the Safety, Tolerability, and Pharmacokinetic (PK) Profile of EGT0001474 in Healthy Volunteers | Theracos | Phase 1 | Completed | Safety and Tolerability of EGT0001474 in Healthy Volunteers | 78 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00854113) |
| June 12, 2007 | NCT00485017 | Efficacy and Safety of THR-4109 in Obese Subjects | Theracos | Phase 2 | Completed | Obesity | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00485017) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 10 |
| Phase 2 | 4 |
| Phase 2/3 | 1 |
| Phase 3 | 6 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 20 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Diabetes Mellitus, Type 2 | 12 |
| Obesity | 2 |
| Weight Loss | 2 |
| Essential Hypertension | 1 |
| Diabetes Mellitus | 1 |
| Overweight | 1 |
| Anorexia | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Mattress manufacturing companies in the United States](https://specstream.ai/data/businesses/mattress-manufacturing-companies/united-states)
- [Sushi restaurants in the United States](https://specstream.ai/data/businesses/sushi-restaurants/united-states)
- [Business law firms in the United States](https://specstream.ai/data/businesses/business-law-firms/united-states)
- [Home builders in the United States](https://specstream.ai/data/businesses/home-builders/united-states)
- [Private jet charter companies in the United States](https://specstream.ai/data/businesses/private-jet-charter-companies/united-states)
- [Appellate practice law firms in the United States](https://specstream.ai/data/businesses/appellate-practice-law-firms/united-states)
